Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUO-E phase 3 trial in advanced or recurrent endometrial cancer
CTR20210547Phase 3Active
- Sponsor
- MedImmune
- Start
- Jun 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, olaparib in endometrial cancer (EC), sponsored by MedImmune. Started Jun 2021; status: active.
02
Drugs
durvalumabolaparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20210547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210547.